Zenicor (ZENI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
13 Feb, 2026Executive summary
Achieved 11% year-over-year revenue growth in 2025, reaching the highest annual result to date.
Positive net income for both Q4 and the full year, marking a turnaround from the previous year's loss.
Growth driven by new and existing customer contracts, with a scalable business model based on per-case billing.
Strengthened liquidity and reduced net debt through two share issues and cost efficiency measures.
Financial highlights
Full-year revenue: 28,042 KSEK (up from 25,306 KSEK in 2024).
Operating income for 2025: 2,229 KSEK (217 KSEK in 2024).
Net income for 2025: 214 KSEK (compared to -2,084 KSEK in 2024).
Q4 revenue: 8,136 KSEK (6,882 KSEK in Q4 2024); Q4 net income: 1,212 KSEK (625 KSEK in Q4 2024).
Earnings per share for 2025: 0.01 SEK (-0.23 SEK in 2024); Q4 EPS: 0.05 SEK (0.07 SEK in Q4 2024).
Outlook and guidance
Positioned for accelerated growth in 2026, supported by a strong order backlog and scalable business model.
Focus on maintaining stable net debt and reinvesting operational surplus for growth.
Latest events from Zenicor
- Rights issue and new contracts support rapid growth in arrhythmia diagnostics and early care.ZENI
Investor Update4 Nov 2025 - Q3 2025 revenue up 10% year-over-year, with positive profit and new growth financing secured.ZENI
Q3 202527 Oct 2025 - Q2 2025 saw 10% revenue growth, positive profit, and key wins in Finland and the UK.ZENI
Q2 202531 Jul 2025 - Revenue growth and positive operating income mark a strong Q3, despite liquidity challenges.ZENI
Q3 202413 Jun 2025 - Q2 2024 saw record Q2 revenue, positive operating profit, and strengthened liquidity.ZENI
Q2 202413 Jun 2025 - Record Q1 revenue and UK contracts drive Zenicor's return to profitability.ZENI
Q1 20256 Jun 2025 - Record revenue and a return to profit set the stage for accelerated growth in 2025.ZENI
Q4 20246 Jun 2025